​
​

Foghorn Therapeutics (FHTX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Foghorn Therapeutics Revenue Highlights

Latest Revenue (Y)

$34.16M

Latest Revenue (Q)

$7.81M

Foghorn Therapeutics Revenue by Period

Foghorn Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$34.16M77.63%
2022-12-31$19.23M1357.77%
2021-12-31$1.32M206.74%
2020-12-31$430.00K100.00%
2019-12-31-100.00%
2018-12-31--

Foghorn Therapeutics generated $34.16M in revenue during NA 2023, up 77.63% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Foghorn Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$7.81M13.36%
2024-06-30$6.89M36.40%
2024-03-31$5.05M-12.46%
2023-12-31$5.77M-66.99%
2023-09-30$17.48M212.16%
2023-06-30$5.60M5.46%
2023-03-31$5.31M26.89%
2022-12-31$4.18M-36.93%
2022-09-30$6.63M47.75%
2022-06-30$4.49M14.54%
2022-03-31$3.92M449.79%
2021-12-31$713.00K1639.02%
2021-09-30$41.00K-85.30%
2021-06-30$279.00K-2.45%
2021-03-31$286.00K13.94%
2020-12-31$251.00K40.22%
2020-09-30$179.00K100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-06-30-100.00%
2018-03-31--

Foghorn Therapeutics generated $7.81M in revenue during Q3 2024, up 13.36% compared to the previous quarter, and up 139.45% compared to the same period a year ago.

Foghorn Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
KYMRKymera Therapeutics$78.59M$3.74M
NRIXNurix Therapeutics$76.99M$12.59M
FHTXFoghorn Therapeutics$34.16M$7.81M
STOKStoke Therapeutics$8.78M$4.89M
MOLNMolecular Partners$7.04M$2.74M
IPSCCentury Therapeutics$2.23M$791.00K
STTKShattuck Labs$1.66M$1.61M
MNOVMediciNova$1.00M-
ANEBAnebulo Pharmaceuticals--
RZLTRezolute--
CGEMCullinan Oncology--
CCCCC4 Therapeutics--
CYTCyteir Therapeutics--
PMVPPMV Pharmaceuticals--
PRLDPrelude Therapeutics--
MLYSMineralys Therapeutics--
GLUEMonte Rosa Therapeutics-$4.70M
EWTXEdgewise Therapeutics--
CSBRChampions Oncology--

FHTX Revenue FAQ

What is Foghorn Therapeutics’s yearly revenue?

Foghorn Therapeutics's yearly revenue for 2023 was $34.16M, representing an increase of 77.63% compared to 2022. The company's yearly revenue for 2022 was $19.23M, representing an increase of 1357.77% compared to 2021. FHTX's yearly revenue for 2021 was $1.32M, representing an increase of 206.74% compared to 2020.

What is Foghorn Therapeutics’s quarterly revenue?

Foghorn Therapeutics's quarterly revenue for Q3 2024 was $7.81M, a 13.36% increase from the previous quarter (Q2 2024), and a -55.33% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $6.89M, a 36.40% increase from the previous quarter (Q1 2024), and a 23.02% increase year-over-year (Q2 2023). FHTX's quarterly revenue for Q1 2024 was $5.05M, a -12.46% decrease from the previous quarter (Q4 2023), and a -4.88% decrease year-over-year (Q1 2023).

What is Foghorn Therapeutics’s revenue growth rate?

Foghorn Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 2489.46%, and for the last 5 years (2019-2023) was 0%.